CIK 0001534120 · Non-accelerated filer<br>Smaller reporting company
Avalo Therapeutics, Inc.
Sign in to watch- Ticker
- AVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 450705648
- Phone
- 410-522-8707
- Business address
- 1500 LIBERTY RIDGE DRIVE, SUITE 321, WAYNE, PA, 19087
- Former names
- Cerecor Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,865,893
- in 5 filings, $1.9M under 10b5-1 plans
Net −$1,865,893. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-17 | Sullivan Christopher Ryan Chief Financial Officer | Sale 10b5-1 | −37,945 | $19.85 | $753K | 43,649 |
| 2026-08-17 | Sullivan Christopher Ryan Chief Financial Officer | Sale 10b5-1 | −3,749 | $19.94 | $75K | 39,900 |
| 2026-08-17 | Sullivan Christopher Ryan Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −37,945 | 130,149 | ||
| 2026-08-17 | Sullivan Christopher Ryan Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,876 | 127,273 | ||
| 2026-08-11 | Riley Jennifer Chief Strategy Officer | Sale | −2,655 | $19.59 | $52K | 37,041 |
| 2026-08-10 | Doyle Mittie Chief Medical Officer | Option exercise 10b5-1 | +679 | $8.04 | $5K | 52,455 |
| 2026-08-10 | Doyle Mittie Chief Medical Officer | Sale 10b5-1 | −679 | $20.00 | $14K | 51,776 |
| 2026-08-10 | Doyle Mittie Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −679 | 114,413 | ||
| 2026-07-27 | Doyle Mittie Chief Medical Officer | Option exercise 10b5-1 | +1,000 | $12.65 | $13K | 52,776 |
| 2026-07-27 | Doyle Mittie Chief Medical Officer | Sale 10b5-1 | −1,000 | $20.00 | $20K | 51,776 |
| 2026-07-27 | Doyle Mittie Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,000 | 124,750 | ||
| 2026-06-30 | Philip Ron M Director | Grant or award · Stock Option (Right to Buy) | +69 | $15.04 | $1K | 69 |
| 2026-06-30 | Doyle Mittie Chief Medical Officer | Option exercise 10b5-1 | +2,875 | $12.65 | $36K | 54,651 |
| 2026-06-30 | Doyle Mittie Chief Medical Officer | Option exercise 10b5-1 | +1,779 | $8.04 | $14K | 56,430 |
| 2026-06-30 | Doyle Mittie Chief Medical Officer | Sale 10b5-1 | −4,654 | $20.00 | $93K | 51,776 |
| 2026-06-30 | Doyle Mittie Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,875 | 125,750 | ||
| 2026-06-30 | Doyle Mittie Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,779 | 115,092 | ||
| 2026-06-30 | Jain Rita Director | Grant or award · Stock Option (Right to Buy) | +1,080 | $15.04 | $16K | 1,080 |
| 2026-06-30 | Lind Kevin Robert Director | Grant or award · Stock Option (Right to Buy) | +1,105 | $15.04 | $17K | 1,105 |
| 2026-06-23 | Philip Ron M Director | Grant or award · Stock Option (Right to Buy) | +40,200 | 40,200 |
Page 2 of 11 · 202 trades